Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04373083
Other study ID # R2810-ONC-1615
Secondary ID 2017-004265-28
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date November 15, 2020
Est. completion date February 20, 2025

Study information

Verified date December 2020
Source Regeneron Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to estimate the efficacy of experimental treatment with the anti-PD-1 antibody cemiplimab (REGN2810) in combination with simultaneous or subsequent radiotherapy (RT) in early-stage favorable classical Hodgkin lymphoma (cHL). Secondary objectives are to assess the safety and feasibility of the 2 experimental strategies.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 20, 2025
Est. primary completion date December 20, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Key Inclusion Criteria: - Histologically proven classical HL - First diagnosis, no previous treatment - Stage I-II without risk factors as defined in the protocol Key Exclusion Criteria: - Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) - Prior malignancy within the previous 5 years (except for locally treatable cancers that have been apparently cured by complete resection) - Prior chemotherapy or radiation therapy - Concurrent disease precluding protocol treatment as defined in the protocol - Pregnancy or breast-feeding - Non-compliance as defined in the protocol Note: Other protocol-defined Inclusion/Exclusion criteria apply

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cemiplimab
Administered in 3-week intervals
Radiation:
Involved-site radiotherapy (IS-RT)
Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Regeneron Pharmaceuticals Sanofi

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) at 1 year From randomization up to 1 year
Secondary PFS at 2 and 3 years From randomization up to 3 years
Secondary Overall survival (OS) at 1, 2, and 3 years From randomization up to 3 years
Secondary Incidence of acute toxicities Up to 90 days after study treatment
Secondary Rate of patients with long-term fatigue using EORTC-QLQ-FA12 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ).
-FA12 module complements the core EORTC QLQ-C30 questionnaire regarding fatigue. Each item can be scored in four dimension on a scale from 1 to 4 with higher scores indicating worse symptoms.
12-18 months after randomization
Secondary Rate of patients with long-term fatigue using EORTC-QLQ-C30 Scores range from 0 to 100. A high scale score represents a higher response level. 12-18 months after randomization
Secondary Quality of life (QoL) using EORTC-QLQ-30 Scores range from 0 to 100. A high scale score represents a higher response level. Up to 3 years
Secondary Rate of early discontinuation of study treatment From first dose to up to 19 weeks
Secondary Frequency of lymphoma treatment administered in addition to study treatment From randomization up to 3 years
Secondary Types of lymphoma treatment administered in addition to study treatment From randomization up to 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Active, not recruiting NCT03617666 - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
Active, not recruiting NCT02191930 - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma Phase 2
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT01393106 - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Terminated NCT00992030 - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Phase 3
Terminated NCT00722865 - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Active, not recruiting NCT05205512 - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial N/A
Recruiting NCT03681561 - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT03250962 - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Recruiting NCT04510610 - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Phase 2/Phase 3
Completed NCT06295211 - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting NCT02256137 - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed NCT02432235 - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Phase 1